$1.45
0.34% today
NYSE, Apr 01, 06:17 pm CET
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

HilleVax Stock price

$1.45
-0.34 18.99% 1M
-0.31 17.61% 6M
-0.62 29.95% YTD
-14.48 90.90% 1Y
-17.64 92.40% 3Y
-17.64 92.40% 5Y
-17.64 92.40% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.14 8.81%
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

Key metrics

Market capitalization $72.22m
Enterprise Value $-74.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.68
P/B ratio (TTM) P/B ratio 0.47
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-106.96m
Free Cash Flow (TTM) Free Cash Flow $-109.31m
Cash position $171.43m
EPS (TTM) EPS $-3.00
P/E forward negative
Short interest 19.77%
Show more

Is HilleVax a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

HilleVax Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a HilleVax forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a HilleVax forecast:

Hold
100%

Financial data from HilleVax

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.20 3.20
48% 48%
-
-3.20 -3.20
48% 48%
-
- Selling and Administrative Expenses 22 22
0% 0%
-
- Research and Development Expense 78 78
27% 27%
-
-104 -104
21% 21%
-
- Depreciation and Amortization 3.20 3.20
48% 48%
-
EBIT (Operating Income) EBIT -107 -107
20% 20%
-
Net Profit -147 -147
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about HilleVax directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HilleVax Stock News

Neutral
GlobeNewsWire
4 days ago
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical co...

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Head office United States
CEO Robert Hershberg
Employees 14
Founded 2020
Website www.hillevax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today